Aspirin’s targeted defence against a stealthy heart valve threat
A large observational study suggests that regular, low-dose aspirin use may help prevent aortic valve calcification and stenosis, but only in individuals with high levels of a specific blood particle called lipoprotein(a) [Lp(a)]. The research, involving nearly 6,600 participants, found that among people with elevated Lp(a), regular aspirin use was associated with a significantly lower risk of developing hardened aortic valves and severe narrowing. However, for those with high LDL (“bad”) cholesterol but normal Lp(a), aspirin showed no such protective benefit, indicating the effect is specific to the unique anti-fibrinolytic properties of Lp(a).
Why it might matter to you:
This study highlights a potential, targeted preventive strategy for a common and serious cardiac condition, moving beyond a one-size-fits-all approach. For clinical training, it underscores the growing importance of personalized cardiovascular risk assessment, where biomarkers like Lp(a) could guide specific therapeutic decisions. It presents a clear example of how understanding a disease’s underlying mechanism can lead to more precise and evidence-based interventions.
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
